DRYTEC
LOE ApproachingNDAINTRAVENOUS, ORALSOLUTION
Approved
Nov 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DRYTEC is an intravenous and oral solution approved by the FDA in 1976 as an NDA product sponsored by GE HealthCare. The mechanism of action, pharmacologic class, and specific indications are not publicly disclosed in available data. This legacy product likely serves diagnostic or therapeutic purposes in a specialized clinical setting.
LOE Approaching
DRYTEC is in late-stage product lifecycle with moderate competitive pressure (30/100), suggesting a consolidating market and smaller, specialized brand team focused on retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DRYTEC currently has zero linked job openings, reflecting its mature, stable market position with minimal commercial expansion. Careers on this product focus on operational excellence, market maintenance, and strategic planning for exclusivity loss rather than growth.
Brand ManagerProduct Manager
Worked on DRYTEC at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.